External | what does this mean?
This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author.
Allfunds indicative IPO price range implies market value of between €6.6 billion to €7.6 billion 3 hours ago
Source: Allfunds Allfunds this morning announces the indicative price range, publication of the Prospectus and start of the offer period of the planned Offering. Juan Alcaraz, Founder and CEO of Allfunds, comments:
“We’re hugely encouraged by the strong initial reaction to our IPO and welcome BlackRock, Jupiter, Mawer, Lazard and Janus Henderson Investors to our shareholder register as cornerstone investors. Allfunds has maintained very positive momentum through the first quarter of 2021, as we look to realise the fantastic opportunity ahead by offering best in class service for our clients, driving growth and continuing the journey we began in 2000. I look forward to the
PolyPeptide Group plans IPO and listing on the Swiss Stock Exchange
EQS Group-News: PolyPeptide Group / Key word(s): IPO
12.04.2021 / 07:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
PolyPeptide Group plans IPO and listing on the Swiss Stock Exchange
3 Min Read
ZURICH (Reuters) - PolyPeptide Group, controlled by a foundation of Swedish billionaire adventurer Frederik Paulsen Jr., said Monday it plans to list a 40% stake on the Swiss stock exchange to finance the contract drug maker’s growth.
The company, which makes ingredients for U.S.-based Novavax Inc’s, COVID-19 vaccine candidate, plans to list in the second quarter.
It plans to place existing shares and a primary offering, with some proceeds to go for potential acquisitions.
PolyPeptide is eyeing “adjacent” business areas, in not only oligonucleotides that can be used in genetic diseases as well as personalised neoantigen cancer immunotherapies, outgoing Chief Executive Jane Salik said in an interview.
Roissy, 12 April 2021 Air France-KLM launches a capital increase without shareholders’ preferential subscription rights, by way of a public offering and.
Air France KLM : KLM launches a capital increase marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.